• 1. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 2. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 3. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 4. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

Deoxyfuconojirimycin Hydrochloride: A Comprehensive Overview

Deoxyfuconojirimycin Hydrochloride, with the CAS number 210174-73-5, is a compound of significant interest in the fields of pharmacology and biochemistry. This compound, also referred to as DFJ HCl, has garnered attention due to its unique structural properties and potential therapeutic applications. Recent studies have highlighted its role in various biological processes, making it a subject of extensive research.

The chemical structure of Deoxyfuconojirimycin Hydrochloride is characterized by a complex arrangement of functional groups, which contribute to its diverse biological activities. Its molecular formula and molecular weight have been well-documented, providing a foundation for further exploration into its pharmacokinetics and pharmacodynamics. Researchers have utilized advanced analytical techniques, such as NMR and mass spectrometry, to elucidate its structural details, ensuring precise characterization for subsequent studies.

One of the most promising aspects of Deoxyfuconojirimycin Hydrochloride lies in its bioactivity. Recent findings suggest that this compound exhibits potent anti-inflammatory properties, making it a potential candidate for treating conditions such as arthritis and inflammatory bowel disease. Additionally, studies have demonstrated its ability to modulate key signaling pathways involved in cellular proliferation and apoptosis, indicating its potential in anticancer therapies.

The synthesis of Deoxyfuconojirimycin Hydrochloride has been optimized through various methodologies, ensuring scalability and reproducibility. Researchers have explored both synthetic and semi-synthetic routes, with a focus on improving yield and purity. These advancements have facilitated large-scale production, paving the way for preclinical and clinical trials.

In terms of therapeutic applications, Deoxyfuconojirimycin Hydrochloride has shown particular promise in the field of oncology. Preclinical studies have demonstrated its ability to inhibit tumor growth and metastasis in animal models, suggesting a potential role in cancer treatment. Furthermore, its selective toxicity towards cancer cells over normal cells has been a focal point of recent investigations, highlighting its potential as a targeted therapy.

The pharmacokinetic profile of Deoxyfuconojirimycin Hydrochloride has also been extensively studied. Research indicates that it exhibits favorable absorption and distribution properties, with moderate clearance rates. These characteristics suggest that it may be suitable for oral administration, enhancing its potential as an orally available therapeutic agent.

In addition to its therapeutic applications, Deoxyfuconojirimycin Hydrochloride has been explored for its role in diagnostic imaging. Its ability to bind specific biomarkers associated with diseases such as cancer has led to investigations into its use as a contrast agent in imaging modalities like MRI and PET scans.

The safety profile of Deoxyfuconojirimycin Hydrochloride has been evaluated through acute and chronic toxicity studies. Results indicate that it exhibits low toxicity at therapeutic doses, with no significant adverse effects observed in preclinical models. These findings underscore its potential for safe use in humans.

In conclusion, Deoxyfuconojirimycin Hydrochloride, with CAS number 210174-73-5, represents a compelling compound with diverse biological activities and therapeutic potential. Its structural properties, bioactivity, synthesis methods, pharmacokinetics, safety profile, and diagnostic applications make it a subject of continued research interest. As advancements in research continue to unfold, the full extent of its therapeutic potential will likely be realized.

• 70956-02-4(1-Deoxynojirimycin)
• 119557-99-2(α-Homonojirimycin)
• 76144-81-5(Mildronate)
• 72432-03-2(Miglitol)
• 19130-96-2(1-Deoxynojirimycin)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)